Polycythemia as rare secondary direct manifestation of acromegaly

Management and single-centre epidemiological data

Gabriele Zoppoli, Federico Bianchi, Andrea Bruzzone, Alessandro Calvia, Caterina Oneto, Caterina Passalia, Enrico Balleari, Davide Bedognetti, Elena Ponomareva, Elena Nazzari, Lara Castelletti, Lucio Castellan, Francesco Minuto, Riccardo Ghio, Diego Ferone

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Polycythemia associated with acromegaly is usually caused by the systemic manifestations of the disease, such as sleep-Apnea or concomitant erythropoietinsecreting kidney tumors. The recognition of underlying pathologies requires a thorough diagnostic process. We report a unique case of acromegaly with polycythemia, not caused by commonly described manifestations of the disease, and receding with octreotide therapy. The medical history of 141 acromegalic patients followed by the Endocrinology Unit of the San Martino University Hospital in Genoa has been also reviewed, together with the literature evidence for similar cases. The diagnostic workflow and 2-years follow-up of a 43-years old acromegalic, polycythemic man with a history of past smoking, moderate hypertension, and mental retardation are described. The hematological parameters of our cohort was retrospectively compared with those of a healthy, age/genderrelated control group as well. Therapy with octreotide LAR, 20 mg i.m. q28d was begun soon after diagnosis of acromegaly in the polycythemic patient. Haematocrit level, hormonal setting, as well as pituitary tumor size and visual perimetry during treatment were recorded. Octreotide LAR treatment normalized hormonal alterations, as well as hematological parameters. Polycythemia has not recurred after 2 years of therapy. The median hemoglobin and hematocrit levels of the retrospectively analyzed cohort of acromegalic were significantly lower than normal ranges of a healthy, age/sex- related control population. In conclusions, polycythemia can be a direct, albeit rare, secondary manifestation of acromegaly, that must be considered during the diagnostic work-up of acromegalic patients presenting with such disorder.

Original languageEnglish
Pages (from-to)209-214
Number of pages6
JournalPituitary
Volume15
Issue number2
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Polycythemia
Acromegaly
Octreotide
Hematocrit
Therapeutics
Visual Field Tests
Workflow
Endocrinology
Sleep Apnea Syndromes
Pituitary Neoplasms
Intellectual Disability
Reference Values
Hemoglobins
Smoking
History
Pathology
Hypertension
Kidney
Control Groups
Population

Keywords

  • Acromegaly
  • GH
  • IGF-I
  • Polycythemia
  • Polycythemia Vera

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Zoppoli, G., Bianchi, F., Bruzzone, A., Calvia, A., Oneto, C., Passalia, C., ... Ferone, D. (2012). Polycythemia as rare secondary direct manifestation of acromegaly: Management and single-centre epidemiological data. Pituitary, 15(2), 209-214. https://doi.org/10.1007/s11102-011-0311-6

Polycythemia as rare secondary direct manifestation of acromegaly : Management and single-centre epidemiological data. / Zoppoli, Gabriele; Bianchi, Federico; Bruzzone, Andrea; Calvia, Alessandro; Oneto, Caterina; Passalia, Caterina; Balleari, Enrico; Bedognetti, Davide; Ponomareva, Elena; Nazzari, Elena; Castelletti, Lara; Castellan, Lucio; Minuto, Francesco; Ghio, Riccardo; Ferone, Diego.

In: Pituitary, Vol. 15, No. 2, 2012, p. 209-214.

Research output: Contribution to journalReview article

Zoppoli, G, Bianchi, F, Bruzzone, A, Calvia, A, Oneto, C, Passalia, C, Balleari, E, Bedognetti, D, Ponomareva, E, Nazzari, E, Castelletti, L, Castellan, L, Minuto, F, Ghio, R & Ferone, D 2012, 'Polycythemia as rare secondary direct manifestation of acromegaly: Management and single-centre epidemiological data', Pituitary, vol. 15, no. 2, pp. 209-214. https://doi.org/10.1007/s11102-011-0311-6
Zoppoli, Gabriele ; Bianchi, Federico ; Bruzzone, Andrea ; Calvia, Alessandro ; Oneto, Caterina ; Passalia, Caterina ; Balleari, Enrico ; Bedognetti, Davide ; Ponomareva, Elena ; Nazzari, Elena ; Castelletti, Lara ; Castellan, Lucio ; Minuto, Francesco ; Ghio, Riccardo ; Ferone, Diego. / Polycythemia as rare secondary direct manifestation of acromegaly : Management and single-centre epidemiological data. In: Pituitary. 2012 ; Vol. 15, No. 2. pp. 209-214.
@article{190f994d9fbd4f4b8443804c89e12181,
title = "Polycythemia as rare secondary direct manifestation of acromegaly: Management and single-centre epidemiological data",
abstract = "Polycythemia associated with acromegaly is usually caused by the systemic manifestations of the disease, such as sleep-Apnea or concomitant erythropoietinsecreting kidney tumors. The recognition of underlying pathologies requires a thorough diagnostic process. We report a unique case of acromegaly with polycythemia, not caused by commonly described manifestations of the disease, and receding with octreotide therapy. The medical history of 141 acromegalic patients followed by the Endocrinology Unit of the San Martino University Hospital in Genoa has been also reviewed, together with the literature evidence for similar cases. The diagnostic workflow and 2-years follow-up of a 43-years old acromegalic, polycythemic man with a history of past smoking, moderate hypertension, and mental retardation are described. The hematological parameters of our cohort was retrospectively compared with those of a healthy, age/genderrelated control group as well. Therapy with octreotide LAR, 20 mg i.m. q28d was begun soon after diagnosis of acromegaly in the polycythemic patient. Haematocrit level, hormonal setting, as well as pituitary tumor size and visual perimetry during treatment were recorded. Octreotide LAR treatment normalized hormonal alterations, as well as hematological parameters. Polycythemia has not recurred after 2 years of therapy. The median hemoglobin and hematocrit levels of the retrospectively analyzed cohort of acromegalic were significantly lower than normal ranges of a healthy, age/sex- related control population. In conclusions, polycythemia can be a direct, albeit rare, secondary manifestation of acromegaly, that must be considered during the diagnostic work-up of acromegalic patients presenting with such disorder.",
keywords = "Acromegaly, GH, IGF-I, Polycythemia, Polycythemia Vera",
author = "Gabriele Zoppoli and Federico Bianchi and Andrea Bruzzone and Alessandro Calvia and Caterina Oneto and Caterina Passalia and Enrico Balleari and Davide Bedognetti and Elena Ponomareva and Elena Nazzari and Lara Castelletti and Lucio Castellan and Francesco Minuto and Riccardo Ghio and Diego Ferone",
year = "2012",
doi = "10.1007/s11102-011-0311-6",
language = "English",
volume = "15",
pages = "209--214",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Polycythemia as rare secondary direct manifestation of acromegaly

T2 - Management and single-centre epidemiological data

AU - Zoppoli, Gabriele

AU - Bianchi, Federico

AU - Bruzzone, Andrea

AU - Calvia, Alessandro

AU - Oneto, Caterina

AU - Passalia, Caterina

AU - Balleari, Enrico

AU - Bedognetti, Davide

AU - Ponomareva, Elena

AU - Nazzari, Elena

AU - Castelletti, Lara

AU - Castellan, Lucio

AU - Minuto, Francesco

AU - Ghio, Riccardo

AU - Ferone, Diego

PY - 2012

Y1 - 2012

N2 - Polycythemia associated with acromegaly is usually caused by the systemic manifestations of the disease, such as sleep-Apnea or concomitant erythropoietinsecreting kidney tumors. The recognition of underlying pathologies requires a thorough diagnostic process. We report a unique case of acromegaly with polycythemia, not caused by commonly described manifestations of the disease, and receding with octreotide therapy. The medical history of 141 acromegalic patients followed by the Endocrinology Unit of the San Martino University Hospital in Genoa has been also reviewed, together with the literature evidence for similar cases. The diagnostic workflow and 2-years follow-up of a 43-years old acromegalic, polycythemic man with a history of past smoking, moderate hypertension, and mental retardation are described. The hematological parameters of our cohort was retrospectively compared with those of a healthy, age/genderrelated control group as well. Therapy with octreotide LAR, 20 mg i.m. q28d was begun soon after diagnosis of acromegaly in the polycythemic patient. Haematocrit level, hormonal setting, as well as pituitary tumor size and visual perimetry during treatment were recorded. Octreotide LAR treatment normalized hormonal alterations, as well as hematological parameters. Polycythemia has not recurred after 2 years of therapy. The median hemoglobin and hematocrit levels of the retrospectively analyzed cohort of acromegalic were significantly lower than normal ranges of a healthy, age/sex- related control population. In conclusions, polycythemia can be a direct, albeit rare, secondary manifestation of acromegaly, that must be considered during the diagnostic work-up of acromegalic patients presenting with such disorder.

AB - Polycythemia associated with acromegaly is usually caused by the systemic manifestations of the disease, such as sleep-Apnea or concomitant erythropoietinsecreting kidney tumors. The recognition of underlying pathologies requires a thorough diagnostic process. We report a unique case of acromegaly with polycythemia, not caused by commonly described manifestations of the disease, and receding with octreotide therapy. The medical history of 141 acromegalic patients followed by the Endocrinology Unit of the San Martino University Hospital in Genoa has been also reviewed, together with the literature evidence for similar cases. The diagnostic workflow and 2-years follow-up of a 43-years old acromegalic, polycythemic man with a history of past smoking, moderate hypertension, and mental retardation are described. The hematological parameters of our cohort was retrospectively compared with those of a healthy, age/genderrelated control group as well. Therapy with octreotide LAR, 20 mg i.m. q28d was begun soon after diagnosis of acromegaly in the polycythemic patient. Haematocrit level, hormonal setting, as well as pituitary tumor size and visual perimetry during treatment were recorded. Octreotide LAR treatment normalized hormonal alterations, as well as hematological parameters. Polycythemia has not recurred after 2 years of therapy. The median hemoglobin and hematocrit levels of the retrospectively analyzed cohort of acromegalic were significantly lower than normal ranges of a healthy, age/sex- related control population. In conclusions, polycythemia can be a direct, albeit rare, secondary manifestation of acromegaly, that must be considered during the diagnostic work-up of acromegalic patients presenting with such disorder.

KW - Acromegaly

KW - GH

KW - IGF-I

KW - Polycythemia

KW - Polycythemia Vera

UR - http://www.scopus.com/inward/record.url?scp=84942303287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942303287&partnerID=8YFLogxK

U2 - 10.1007/s11102-011-0311-6

DO - 10.1007/s11102-011-0311-6

M3 - Review article

VL - 15

SP - 209

EP - 214

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 2

ER -